89bio, Inc.
ETNB
$9.37
-$0.22-2.29%
| 12/31/2023 | 09/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -3.96% | 9.90% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.73% | -6.61% | |||
| Operating Income | -4.73% | 6.61% | |||
| Income Before Tax | -4.73% | 9.55% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -15.87% | 9.55% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -15.87% | 9.55% | |||
| EBIT | -4.73% | 6.61% | |||
| EBITDA | -4.72% | 6.61% | |||
| EPS Basic | -9.61% | 12.16% | |||
| Normalized Basic EPS | -4.36% | 12.17% | |||
| EPS Diluted | -9.61% | 12.16% | |||
| Normalized Diluted EPS | -4.36% | 12.17% | |||
| Average Basic Shares Outstanding | 5.71% | 2.98% | |||
| Average Diluted Shares Outstanding | 5.71% | 2.98% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
